HK1259059A1 - 控制了重鏈與輕鏈的締合的抗原結合分子 - Google Patents

控制了重鏈與輕鏈的締合的抗原結合分子

Info

Publication number
HK1259059A1
HK1259059A1 HK19101559.0A HK19101559A HK1259059A1 HK 1259059 A1 HK1259059 A1 HK 1259059A1 HK 19101559 A HK19101559 A HK 19101559A HK 1259059 A1 HK1259059 A1 HK 1259059A1
Authority
HK
Hong Kong
Prior art keywords
chain
conjugation
antigen
regulated
heavy
Prior art date
Application number
HK19101559.0A
Other languages
English (en)
Inventor
倉持太一
川添明里
廣庭奈緒香
井川智之
Original Assignee
中外制藥株式會社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48192053&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1259059(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 中外制藥株式會社 filed Critical 中外制藥株式會社
Publication of HK1259059A1 publication Critical patent/HK1259059A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK19101559.0A 2011-10-31 2019-01-29 控制了重鏈與輕鏈的締合的抗原結合分子 HK1259059A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2011238873 2011-10-31

Publications (1)

Publication Number Publication Date
HK1259059A1 true HK1259059A1 (zh) 2019-11-22

Family

ID=48192053

Family Applications (2)

Application Number Title Priority Date Filing Date
HK19101559.0A HK1259059A1 (zh) 2011-10-31 2019-01-29 控制了重鏈與輕鏈的締合的抗原結合分子
HK19101558.1A HK1259058A1 (zh) 2011-10-31 2019-01-29 控制了重鏈與輕鏈的締合的抗原結合分子

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK19101558.1A HK1259058A1 (zh) 2011-10-31 2019-01-29 控制了重鏈與輕鏈的締合的抗原結合分子

Country Status (12)

Country Link
US (2) US11851476B2 (zh)
EP (1) EP2787078B1 (zh)
JP (2) JP6371059B2 (zh)
KR (2) KR102168733B1 (zh)
CN (3) CN104011207B (zh)
BR (1) BR112014010257A2 (zh)
CA (1) CA2853230C (zh)
ES (1) ES2732712T3 (zh)
HK (2) HK1259059A1 (zh)
MX (1) MX359775B (zh)
RU (1) RU2681885C2 (zh)
WO (1) WO2013065708A1 (zh)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3623473A1 (en) 2005-03-31 2020-03-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
EP4001409A1 (en) 2006-03-31 2022-05-25 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
ES2654040T3 (es) 2006-03-31 2018-02-12 Chugai Seiyaku Kabushiki Kaisha Método de modificación de anticuerpos para la purificación de anticuerpos biespecíficos
WO2009041643A1 (ja) 2007-09-26 2009-04-02 Chugai Seiyaku Kabushiki Kaisha Cdrのアミノ酸置換により抗体の等電点を改変する方法
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
CN102369214B (zh) 2009-04-07 2019-04-12 罗氏格黎卡特股份公司 三价、双特异性抗体
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
CN105585630B (zh) 2010-07-29 2020-09-15 Xencor公司 具有修改的等电点的抗体
MY166429A (en) 2010-11-17 2018-06-26 Chugai Pharmaceutical Co Ltd Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
TWI638833B (zh) 2010-11-30 2018-10-21 中外製藥股份有限公司 細胞傷害誘導治療劑
WO2012116927A1 (en) 2011-02-28 2012-09-07 F. Hoffmann-La Roche Ag Monovalent antigen binding proteins
BR112013019975A2 (pt) 2011-02-28 2017-08-01 Hoffmann La Roche proteínas de ligação de antígeno, composição farmacêutica, uso de uma proteína de ligação de antígeno, método para o tratamento de um paciente e método para a preparação de uma proteína de ligação de antígeno, ácido nucleico, vetor e célula hospedeira"
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
RU2681885C2 (ru) 2011-10-31 2019-03-13 Чугаи Сейяку Кабусики Кайся Антигенсвязывающая молекула с регулируемой конъюгацией между тяжелой цепью и легкой цепью
EP2836512B1 (en) 2012-04-11 2018-10-24 F.Hoffmann-La Roche Ag Improved antibody light chains
WO2014055784A1 (en) 2012-10-03 2014-04-10 Zymeworks Inc. Methods of quantitating heavy and light chain polypeptide pairs
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
KR102411491B1 (ko) 2012-11-28 2022-06-22 자임워크스 인코포레이티드 가공된 면역글로불린 중쇄-경쇄 쌍 및 이들의 용도
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
DK2943511T3 (da) 2013-01-14 2019-10-21 Xencor Inc Nye heterodimeriske proteiner
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
CA2897987A1 (en) 2013-01-15 2014-07-24 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
CA2900764A1 (en) * 2013-02-08 2014-08-14 Stemcentrx, Inc. Novel multispecific constructs
KR101813708B1 (ko) * 2013-03-13 2017-12-29 (주) 아이벤트러스 소수성 상호작용 부위내에 전기적 상호작용이 도입된 단백질 및 이의 제조방법
DK2970486T3 (en) 2013-03-15 2018-08-06 Xencor Inc MODULATION OF T-CELLS WITH BISPECIFIC ANTIBODIES AND FC-FUSIONS
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
EP3050896B1 (en) 2013-09-27 2021-07-07 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
RU2016115866A (ru) 2013-10-11 2017-11-16 Ф. Хоффманн-Ля Рош Аг Мультиспецифические антитела с обменянными доменами и одинаковыми вариабельными доменами легкой цепи
SI3122781T1 (sl) 2014-03-28 2020-03-31 Xencor, Inc. Bispecifična protitelesa, ki se vežejo na CD38 in CD3
UA117289C2 (uk) * 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
TWI726842B (zh) 2014-04-07 2021-05-11 日商中外製藥股份有限公司 免疫活化抗原結合分子
AU2015260230A1 (en) 2014-05-13 2016-11-17 Chugai Seiyaku Kabushiki Kaisha T cell-redirected antigen-binding molecule for cells having immunosuppression function
RU2729467C2 (ru) 2014-05-28 2020-08-06 Займворкс Инк. Модифицированные антигенсвязывающие полипептидные конструкции и их применение
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
EP3204416A1 (en) * 2014-10-09 2017-08-16 EngMab AG Bispecific antibodies against cd3epsilon and ror1 for use in the treatment of ovarian cancer
JP6708635B2 (ja) * 2014-10-09 2020-06-10 エンクマフ エスアーエールエル ＣＤ３εおよびＲＯＲ１に対する二特異性抗体
MA41019A (fr) 2014-11-26 2021-05-05 Xencor Inc Anticorps hétérodimériques se liant aux antigènes cd3 et cd38
CN107207610B (zh) 2014-11-26 2022-09-09 森科股份有限公司 结合cd3和肿瘤抗原的异二聚体抗体
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
CN107001482B (zh) 2014-12-03 2021-06-15 豪夫迈·罗氏有限公司 多特异性抗体
WO2016105450A2 (en) 2014-12-22 2016-06-30 Xencor, Inc. Trispecific antibodies
JP6932649B2 (ja) * 2015-02-16 2021-09-08 ロンザ リミテッドＬｏｎｚａ Ｌｉｍｉｔｅｄ Ｃｌ及び／又はｃｈ１が突然変異された薬剤コンジュゲーションのための抗体
US10227411B2 (en) 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
US11142587B2 (en) 2015-04-01 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
AU2016252773B2 (en) * 2015-04-24 2022-06-02 Genentech, Inc. Multispecific antigen-binding proteins
CR20210429A (es) 2015-06-24 2021-09-24 Hoffmann La Roche ANTICUERPOS ANTI-RECEPTOR DE TRANSFERRINA CON AFINIDAD DISEÑADA (Divisional 2017-0562)
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
EP3150636A1 (en) * 2015-10-02 2017-04-05 F. Hoffmann-La Roche AG Tetravalent multispecific antibodies
IL312251A (en) * 2015-10-02 2024-06-01 Hoffmann La Roche Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
FI3359576T3 (fi) 2015-10-08 2025-01-29 Zymeworks Bc Inc Antigeeniä sitovia polypeptidirakenteita, jotka käsittävät kappa- ja lamba-kevytketjuja, ja niiden käyttötapoja
JP6931329B2 (ja) 2015-11-18 2021-09-01 中外製薬株式会社 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
JP6925278B2 (ja) 2015-11-18 2021-08-25 中外製薬株式会社 液性免疫応答の増強方法
CA3007030A1 (en) 2015-12-07 2017-06-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and psma
EP3395835B1 (en) 2015-12-25 2021-02-03 Chugai Seiyaku Kabushiki Kaisha Antibody having enhanced activity, and method for modifying same
WO2017117179A1 (en) * 2015-12-28 2017-07-06 Massachusetts Institute Of Technology Bispecific antibodies having constant region mutations and uses therefor
CA3004288A1 (en) 2015-12-28 2017-07-06 Nobuyuki Tanaka Method for promoting efficiency of purification of fc region-containing polypeptide
AU2017209099A1 (en) 2016-01-22 2018-08-02 Janssen Biotech, Inc. Anti-ROR1 antibodies, ROR1 x CD3 bispecific antibodies, and methods of using the same
KR101834708B1 (ko) 2016-03-14 2018-03-06 추가이 세이야쿠 가부시키가이샤 암의 치료에 이용하기 위한 세포상해 유도 치료제
HUE068801T2 (hu) 2016-06-14 2025-01-28 Xencor Inc Bispecifikus kontrollpont-gátló antitestek
KR20190020341A (ko) 2016-06-28 2019-02-28 젠코어 인코포레이티드 소마토스타틴 수용체 2에 결합하는 이종이량체 항체
KR102098919B1 (ko) * 2016-07-19 2020-04-23 (주) 아이벤트러스 이중 특이성 단백질 및 이의 제조 방법
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
SG11201903304YA (en) 2016-10-14 2019-05-30 Xencor Inc IL15/IL15Ra HETERODIMERIC FC-FUSION PROTEINS
EP3589650A1 (en) * 2017-03-02 2020-01-08 Novartis AG Engineered heterodimeric proteins
AU2018241881B2 (en) * 2017-03-27 2024-10-10 Biomunex Pharmaceuticals Stable multispecific antibodies
AU2018291497A1 (en) 2017-06-30 2020-01-16 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
US10759870B2 (en) * 2017-09-29 2020-09-01 Chugai Seiyaku Kabushiki Kaisha Multispecific antigen-binding molecules having blood coagulation factor VIII (FVIII) cofactor function-substituting activity and pharmaceutical formulations containing such a molecule as an active ingredient
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
CA3082383A1 (en) 2017-11-08 2019-05-16 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-pd-1 sequences
IL275426B1 (en) 2017-12-19 2024-11-01 Xencor Inc Engineered il-2 fc fusion proteins
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
WO2019148410A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1 antibodies
US10982006B2 (en) 2018-04-04 2021-04-20 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
CN112437777A (zh) 2018-04-18 2021-03-02 Xencor股份有限公司 包含IL-15/IL-15RA Fc融合蛋白和TIM-3抗原结合结构域的靶向TIM-3的异源二聚体融合蛋白
WO2019204665A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
KR20210069641A (ko) 2018-10-03 2021-06-11 젠코어 인코포레이티드 IL-12 이종이량체 Fc-융합 단백질
CN113795508A (zh) 2018-12-24 2021-12-14 赛诺菲 具有突变型Fab结构域的多特异性结合蛋白
AU2020232605A1 (en) 2019-03-01 2021-10-21 Xencor, Inc. Heterodimeric antibodies that bind ENPP3 and CD3
SG11202112307YA (en) 2019-07-10 2021-12-30 Chugai Pharmaceutical Co Ltd Claudin-6 binding molecules and uses thereof
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
EP4200332A1 (en) 2020-08-19 2023-06-28 Xencor, Inc. Anti-cd28 and/or anti-b7h3 compositions
AU2021343008A1 (en) * 2020-09-18 2023-06-01 Chugai Seiyaku Kabushiki Kaisha Anti-hla-dq2.5 antibody and its use for the treatment of celiac disease
CN114437226A (zh) * 2020-11-05 2022-05-06 杭州菁因康生物科技有限公司 制备双特异性抗体的方法
MX2023010499A (es) 2021-03-09 2023-09-18 Xencor Inc Anticuerpos heterodimericos que se unen a cd3 y cldn6.
JP2024509274A (ja) 2021-03-10 2024-02-29 ゼンコア インコーポレイテッド Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体
MX2023012408A (es) 2021-04-30 2023-10-31 Hoffmann La Roche Dosis para tratamiento conjunto con anticuerpo biespecifico anti-cd20/anti-cd3 y conjugado anticuerpo farmaco anti-cd79b.
WO2023053282A1 (ja) 2021-09-29 2023-04-06 中外製薬株式会社 がんの治療に用いるための細胞傷害誘導治療剤
AR127269A1 (es) 2021-10-08 2024-01-03 Chugai Pharmaceutical Co Ltd Formulación de anticuerpo anti-hla-dq2.5

Family Cites Families (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58201994A (ja) 1982-05-21 1983-11-25 Hideaki Hagiwara 抗原特異的ヒト免疫グロブリンの生産方法
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
WO1992020791A1 (en) 1990-07-10 1992-11-26 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
JP3540315B2 (ja) 1991-09-23 2004-07-07 メディカル リサーチ カウンシル キメラ抗体の製造−組合せアプローチ
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US6025165A (en) 1991-11-25 2000-02-15 Enzon, Inc. Methods for producing multivalent antigen-binding proteins
WO1993011236A1 (en) 1991-12-02 1993-06-10 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
AU3328493A (en) 1991-12-17 1993-07-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
JP3507073B2 (ja) 1992-03-24 2004-03-15 ケンブリッジ アンティボディー テクノロジー リミティド 特異的結合対の成員の製造方法
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
ATE381614T1 (de) 1992-07-24 2008-01-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
ZA936260B (en) 1992-09-09 1994-03-18 Smithkline Beecham Corp Novel antibodies for conferring passive immunity against infection by a pathogen in man
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
WO1995015393A1 (fr) 1993-12-03 1995-06-08 Asahi Kasei Kogyo Kabushiki Kaisha Nouveau vecteur de detection d'expression
JPH09506508A (ja) 1993-12-03 1997-06-30 メディカル リサーチ カウンシル 組換え結合タンパク質およびペプチド
WO1996002576A1 (fr) 1994-07-13 1996-02-01 Chugai Seiyaku Kabushiki Kaisha Anticorps humain reconstitue contre l'interleukine-8 humaine
US6485943B2 (en) * 1995-01-17 2002-11-26 The University Of Chicago Method for altering antibody light chain interactions
WO1996026648A1 (en) 1995-02-28 1996-09-06 The Procter & Gamble Company Preparation of noncarbonated beverage products having superior microbial stability
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6018032A (en) 1995-09-11 2000-01-25 Kyowa Hakko Kogyo Co., Ltd. Antibody against human interleukin-5-receptor α chain
IL129164A (en) 1996-09-26 2007-05-15 Chugai Pharmaceutical Co Ltd An antibody against peptides associated with human parathyroid hormone
FR2761994B1 (fr) 1997-04-11 1999-06-18 Centre Nat Rech Scient Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
DK0979281T3 (da) 1997-05-02 2005-11-21 Genentech Inc Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US7029652B2 (en) 1998-09-16 2006-04-18 The Regents Of The University Of California Method of treating tumors
WO2000018806A1 (de) 1998-09-25 2000-04-06 Horst Lindhofer Bispezifische und trispezifische antikörper, die spezifisch mit induzierbaren oberflächenantigenen als operationelle zielstrukturen reagieren
MX353234B (es) 1999-01-15 2018-01-08 Genentech Inc Variantes de polipeptidos con función efectora alterada.
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
CA2409991A1 (en) 2000-05-24 2001-11-29 Imclone Systems Incorporated Bispecific immunoglobulin-like antigen binding proteins and method of production
CN1294148C (zh) 2001-04-11 2007-01-10 中国科学院遗传与发育生物学研究所 环状单链三特异抗体
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
WO2003068801A2 (en) 2002-02-11 2003-08-21 Genentech, Inc. Antibody variants with faster antigen association rates
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20040110226A1 (en) 2002-03-01 2004-06-10 Xencor Antibody optimization
US7736652B2 (en) 2002-03-21 2010-06-15 The Regents Of The University Of California Antibody fusion proteins: effective adjuvants of protein vaccination
JP2004086862A (ja) 2002-05-31 2004-03-18 Celestar Lexico-Sciences Inc タンパク質相互作用情報処理装置、タンパク質相互作用情報処理方法、プログラム、および、記録媒体
US20050130224A1 (en) 2002-05-31 2005-06-16 Celestar Lexico- Sciences, Inc. Interaction predicting device
EP1517921B1 (en) 2002-06-28 2006-06-07 Domantis Limited Dual specific ligands with increased serum half-life
US20060235208A1 (en) 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
DK3284753T3 (da) 2002-10-17 2021-07-05 Genmab As Humane monoklonale antistoffer mod cd20 til anvendelse i behandlingen af multipel sclerose
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
CA2536408A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
WO2005035753A1 (ja) 2003-10-10 2005-04-21 Chugai Seiyaku Kabushiki Kaisha 機能蛋白質を代替する二重特異性抗体
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
AU2004308439A1 (en) 2003-12-22 2005-07-14 Centocor, Inc. Methods for generating multimeric molecules
SG10201606980VA (en) 2004-06-03 2016-10-28 Novimmune Sa Anti-cd3 antibodies and methods of use thereof
EP1674111B1 (en) 2004-07-09 2010-11-03 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody
BR122018016031B8 (pt) 2004-08-04 2021-07-27 Applied Molecular Evolution Inc processo para produzir um anticorpo monoclonal variante com resposta de adcc realçada
CA2577082A1 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
WO2006031994A2 (en) 2004-09-14 2006-03-23 Xencor, Inc. Monomeric immunoglobulin fc domains
AU2006204791A1 (en) 2005-01-12 2006-07-20 Xencor, Inc Antibodies and Fc fusion proteins with altered immunogenicity
WO2006105338A2 (en) 2005-03-31 2006-10-05 Xencor, Inc. Fc VARIANTS WITH OPTIMIZED PROPERTIES
EP1870458B1 (en) 2005-03-31 2018-05-09 Chugai Seiyaku Kabushiki Kaisha sc(Fv)2 STRUCTURAL ISOMERS
EP3623473A1 (en) 2005-03-31 2020-03-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
US20100003254A1 (en) 2005-04-08 2010-01-07 Chugai Seiyaku Kabushiki Kaisha Antibody Substituting for Function of Blood Coagulation Factor VIII
US9241994B2 (en) * 2005-06-10 2016-01-26 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical compositions containing sc(Fv)2
US20090028854A1 (en) 2005-06-10 2009-01-29 Chugai Seiyaku Kabushiki Kaisha sc(Fv)2 SITE-DIRECTED MUTANT
DK1931709T3 (en) 2005-10-03 2017-03-13 Xencor Inc FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES
WO2007053659A2 (en) 2005-11-01 2007-05-10 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method of screening for hepatocellular carcinoma
EP1820513A1 (en) 2006-02-15 2007-08-22 Trion Pharma Gmbh Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies
TW200745163A (en) 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
EP1999154B1 (en) 2006-03-24 2012-10-24 Merck Patent GmbH Engineered heterodimeric protein domains
EP4001409A1 (en) 2006-03-31 2022-05-25 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
CN101460622A (zh) * 2006-03-31 2009-06-17 中外制药株式会社 用于纯化双特异性抗体的抗体修饰方法
ES2654040T3 (es) 2006-03-31 2018-02-12 Chugai Seiyaku Kabushiki Kaisha Método de modificación de anticuerpos para la purificación de anticuerpos biespecíficos
US20090258001A1 (en) 2006-06-06 2009-10-15 Paul Ponath Administration of anti-CD3 antibodies in the treatment of autoimmune diseases
GB0611116D0 (en) 2006-06-06 2006-07-19 Oxford Genome Sciences Uk Ltd Proteins
US20090182127A1 (en) 2006-06-22 2009-07-16 Novo Nordisk A/S Production of Bispecific Antibodies
US20110236374A1 (en) 2007-01-24 2011-09-29 Kyowa Hakko Kirin Co., Ltd. Genetically recombinant antibody composition capable of binding specifically to ganglioside gm2
MX2009010282A (es) 2007-03-29 2009-10-12 Genmab As Anticuerpos biespecificos y metodos para su produccion.
SG195609A1 (en) 2007-04-03 2013-12-30 Amgen Res Munich Gmbh Cross-species-specific binding domain
WO2009011941A2 (en) 2007-04-04 2009-01-22 The Government Of U.S.A., As Represented By The Secretary, Departmetnt Of Health & Human Services Monoclonal antibodies against dengue and other viruses with deletion in fc region
AU2008255352B2 (en) 2007-05-31 2014-05-22 Genmab A/S Stable IgG4 antibodies
ES2540854T3 (es) 2007-06-29 2015-07-14 Merck Sharp & Dohme Corp. Usos de antagonistas MDL-1
CN101874041B (zh) 2007-09-26 2013-06-19 中外制药株式会社 抗体恒定区修饰体
EP2203180B1 (en) 2007-10-22 2012-11-21 Merck Serono S.A. Single ifn-beta fused to a mutated igg fc fragment
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
SI2235064T1 (sl) 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
AU2009228158B2 (en) 2008-03-27 2014-02-27 Zymogenetics, Inc. Compositions and methods for inhibiting PDGFRbeta and VEGF-A
SG10201608379YA (en) 2008-04-11 2016-11-29 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
AU2009241589B2 (en) 2008-04-29 2013-10-10 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
MX2011003133A (es) 2008-09-26 2011-04-21 Roche Glycart Ag Anticuerpos biespecificos anti-egfr/anti-igf-1r.
DE202008016028U1 (de) 2008-12-04 2010-04-15 Melitta Haushaltsprodukte Gmbh & Co. Kg Behälter zur Aufbewahrung von Gegenständen
US20120100140A1 (en) 2009-01-23 2012-04-26 Biogen Idec Ma Inc. Stabilized fc polypeptides with reduced effector function and methods of use
NZ594514A (en) 2009-03-05 2013-06-28 Abbott Lab Interleukin-17 BINDING PROTEINS
US20120071634A1 (en) 2009-03-19 2012-03-22 Chugai Seiyaku Kabushiki Kaisha Antibody Constant Region Variant
US9228017B2 (en) 2009-03-19 2016-01-05 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
EP2233500A1 (en) 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
MX2011010264A (es) 2009-04-01 2011-10-11 Genentech Inc Anticuerpos anti-fcrh5 e inmunoconjugados y metodos de uso.
CN102369214B (zh) 2009-04-07 2019-04-12 罗氏格黎卡特股份公司 三价、双特异性抗体
CA2759233C (en) 2009-04-27 2019-07-16 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
CN102459344A (zh) 2009-05-15 2012-05-16 中外制药株式会社 抗axl抗体
RU2522002C2 (ru) 2009-06-26 2014-07-10 Ридженерон Фармасьютикалз, Инк. Легковыделяемые биспецифические антитела с природным иммуноглобулиновым форматом
US10053513B2 (en) 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
US20130018174A1 (en) 2009-12-25 2013-01-17 Chugai Seiyaku Kabushiki Kaisha Polypeptide modification method for purifying polypeptide multimers
KR101913440B1 (ko) 2010-03-02 2018-10-30 교와 핫꼬 기린 가부시키가이샤 개변 항체 조성물
EP2543730B1 (en) 2010-03-04 2018-10-31 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
RS65965B1 (sr) 2010-04-20 2024-10-31 Genmab As Proteini koji sadrže fc heterodimernih antitela i postupci njihove proizvodnje
KR101860963B1 (ko) 2010-04-23 2018-05-24 제넨테크, 인크. 이종다량체 단백질의 생산
JP6022444B2 (ja) 2010-05-14 2016-11-09 ライナット ニューロサイエンス コーポレイション ヘテロ二量体タンパク質ならびにそれを生産および精製するための方法
US9862769B2 (en) 2010-05-27 2018-01-09 Genmab A/S Monoclonal antibodies against HER2
CA2808154A1 (en) 2010-08-13 2012-02-16 Medimmmune Limited Monomeric polypeptides comprising variant fc regions and methods of use
RS59589B1 (sr) 2010-11-05 2019-12-31 Zymeworks Inc Dizajniranje stabilnog heterodimernog antitela sa mutacijama u fc domenu
MY166429A (en) 2010-11-17 2018-06-26 Chugai Pharmaceutical Co Ltd Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
TWI638833B (zh) 2010-11-30 2018-10-21 中外製藥股份有限公司 細胞傷害誘導治療劑
EP2679681B2 (en) 2011-02-25 2023-11-15 Chugai Seiyaku Kabushiki Kaisha FcgammaRIIB-specific FC antibody
KR20200052383A (ko) 2011-03-25 2020-05-14 아이크노스 사이언스 에스. 아. 헤테로 이량체 면역글로불린
DK2771364T3 (da) 2011-10-27 2019-08-19 Genmab As Fremstilling af heterodimere proteiner
RU2681885C2 (ru) * 2011-10-31 2019-03-13 Чугаи Сейяку Кабусики Кайся Антигенсвязывающая молекула с регулируемой конъюгацией между тяжелой цепью и легкой цепью
MX358862B (es) 2011-11-04 2018-09-06 Zymeworks Inc Diseño de anticuerpo heterodimérico estable con mutaciones en el domino fc.
GB201203051D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
EA035344B1 (ru) 2012-04-20 2020-05-29 Мерюс Н.В. Способ получения двух антител из одной клетки-хозяина
US9714291B2 (en) 2012-10-05 2017-07-25 Kyowa Hakko Kirin Co., Ltd Heterodimer protein composition
CA2889951C (en) 2012-11-02 2023-04-18 Zymeworks Inc. Crystal structures of heterodimeric fc domains
EP3050896B1 (en) 2013-09-27 2021-07-07 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
US11142587B2 (en) 2015-04-01 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
WO2017205014A1 (en) 2016-05-26 2017-11-30 Qilu Puget Sound Biotherapeutics Corporation Mixtures of antibodies
KR102098919B1 (ko) 2016-07-19 2020-04-23 (주) 아이벤트러스 이중 특이성 단백질 및 이의 제조 방법
EP3619238A4 (en) 2017-05-02 2021-02-24 Chugai Seiyaku Kabushiki Kaisha CYTOTOXICITY INDUCING THERAPEUTIC
AU2018281045A1 (en) 2017-06-05 2019-12-12 Janssen Biotech, Inc. Engineered multispecific antibodies and other multimeric proteins with asymmetrical CH2-CH3 region mutations
US10759870B2 (en) * 2017-09-29 2020-09-01 Chugai Seiyaku Kabushiki Kaisha Multispecific antigen-binding molecules having blood coagulation factor VIII (FVIII) cofactor function-substituting activity and pharmaceutical formulations containing such a molecule as an active ingredient
EP3732195A4 (en) 2017-12-28 2022-02-09 Chugai Seiyaku Kabushiki Kaisha CYTOTOXICITY-INDUCING THERAPEUTIC
US12065500B2 (en) 2018-05-16 2024-08-20 Janssen Biotech, Inc. Methods of treating cancers and enhancing efficacy of T cell redirecting therapeutics
JPWO2021201202A1 (zh) 2020-04-02 2021-10-07

Also Published As

Publication number Publication date
JP6557286B2 (ja) 2019-08-07
KR20200123842A (ko) 2020-10-30
KR20140084249A (ko) 2014-07-04
KR102168733B1 (ko) 2020-10-23
JPWO2013065708A1 (ja) 2015-04-02
MX2014005045A (es) 2014-08-22
CN109111524A (zh) 2019-01-01
ES2732712T3 (es) 2019-11-25
US20200087380A1 (en) 2020-03-19
JP6371059B2 (ja) 2018-08-08
JP2017212981A (ja) 2017-12-07
US20140370020A1 (en) 2014-12-18
RU2681885C2 (ru) 2019-03-13
HK1259058A1 (zh) 2019-11-22
CN104011207A (zh) 2014-08-27
CN109134658A (zh) 2019-01-04
EP2787078A4 (en) 2015-06-17
MX359775B (es) 2018-10-10
EP2787078A1 (en) 2014-10-08
CN104011207B (zh) 2018-09-18
EP2787078B1 (en) 2019-05-22
WO2013065708A1 (ja) 2013-05-10
BR112014010257A2 (pt) 2017-04-18
US11851476B2 (en) 2023-12-26
KR102398736B1 (ko) 2022-05-16
CN109134658B (zh) 2022-10-14
CA2853230A1 (en) 2013-05-10
RU2014122028A (ru) 2015-12-10
CA2853230C (en) 2021-11-23
CN109111524B (zh) 2022-10-28

Similar Documents

Publication Publication Date Title
HK1259058A1 (zh) 控制了重鏈與輕鏈的締合的抗原結合分子
IL272615B (en) Humanized antibodies that recognize alpha-synuclein, preparations containing them and their uses
IL267225B (en) Bispecific igg4 antibodies are asymmetrically sequenced
HK1203309A1 (zh) 抗體-藥物綴合物以及相關化合物、組合物和方法
HK1202563A1 (zh) 序列對稱性的修飾的 雙特異性抗體
IL245556B (en) A conjugate containing oxyntomodulin and a fragment of immunoglobulin, and its use
SMT201900115T1 (it) Molecola di fv di legame di antigene multivalente
LT2794658T (lt) Bispecifinė antikūno molekulė
EP2841453A4 (en) HUMANIZED AND CHIMERIC C3 ANTI-FACTOR ANTIBODIES AND USES THEREOF
ZA201206835B (en) New humanized anti-cd20 monoclonal antibory
EP2746394A4 (en) ANTIBODY AND COMPOSITION CONTAINING THE SAME
HK1204657A1 (zh) 具有修飾的 的抗-涎免凝集素 抗體
HK1185088A1 (zh) 人源化 抗體
PL2663585T3 (pl) Związki oligomocznika oraz sposób ich wytwarzania i ich zastosowanie
EP2669297A4 (en) HUMANIZED L4-H3 ANTI-EGFR ANTIBODY AND CODING GENE
GB201108070D0 (en) Angels gate
GB201112490D0 (en) Gate catches